January 24, 2020 / 6:17 AM / a month ago

Roche's Tecentriq fails trial in urothelial cancer

ZURICH, Jan 24 (Reuters) - Roche's immunotherapy Tecentriq failed a late-stage clinical trial in a form of urothelial cancer, the Swiss drugmaker said on Friday.

The study evaluating Tecentriq as an after-surgery monotherapy did not meet its primary endpoint of disease-free survival compared to observation in people with muscle-invasive urothelial cancer, Roche said. Safety for Tecentriq appeared consistent with the known safety profile of the medicine, and no new safety signals were identified.

"Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is very difficult, and we are disappointed that we were not able to significantly prolong disease-free survival," said Levi Garraway, chief medical officer. "We remain committed to exploring the potential benefits of immunotherapy for more people with early cancers." (Reporting by Michael Shields)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below